Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Fineline Cube Jul 20, 2026
Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Fineline Cube Jul 20, 2026
Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Fineline Cube Jul 20, 2026
Company Drug

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

Fineline Cube Jul 20, 2026
Company Drug

Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals

Fineline Cube May 30, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the receipt of marketing...

Company Deals

CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals

Fineline Cube May 30, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...

Company Medical Device

Acotec Scientific’s E-Peridge Balloon Catheter Approved by China’s NMPA

Fineline Cube May 30, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Company Drug

Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013

Fineline Cube May 30, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received separate marketing...

Company Drug

NMPA Approves Mabwell’s 8MW0511 for Febrile Neutropenia Prevention

Fineline Cube May 30, 2025

China’s National Medical Products Administration (NMPA) has approved Mabwell (Shanghai) Bioscience Co., Ltd’s (SHA: 688062)...

Company Drug

Hinova’s Deutenzalutamide Approved for Metastatic Prostate Cancer in China

Fineline Cube May 30, 2025

Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) announced that the New Drug Application (NDA) for...

Company Drug

Sino Biopharmaceutical’s TQB2868 Shows Strong Results in Phase II Pancreatic Cancer Trial

Fineline Cube May 30, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented data from its Phase II clinical trial (TQB2868-ALTN-II-01)...

Company Drug

Hansoh Pharma Gains NMPA Clinical Approvals for HS-10510, HS-10542, and HS-20118

Fineline Cube May 30, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received separate clinical...

Company Drug

Genor Biopharma Gains NMPA Approval for CDK4/6 Inhibitor Lerociclib in China

Fineline Cube May 30, 2025

China’s Genor Biopharma Co., Ltd (HKG: 6998) announced that it has received marketing clearance from...

Company Deals

Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development

Fineline Cube May 30, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...

Company Deals

Danaher Partners with AstraZeneca to Advance Precision Medicine

Fineline Cube May 30, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with...

Company Drug

Innovent Biologics Doses First Patient in Phase III Psoriasis Trial for Picankibart

Fineline Cube May 30, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first subject dosing in a Phase III...

Company Drug

GSK Halts PIVOT-PO Trial Early as Tebipenem HBr Meets Efficacy Targets for cUTI

Fineline Cube May 30, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the early termination of the pivotal Phase...

Company Drug

Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency

Fineline Cube May 30, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...

Company Drug

Regend Therapeutics Gains NMPA Approval for Phase I/II Study of REGEND003 in Diabetes-Related CKD

Fineline Cube May 30, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that it has received approval from China’s...

Company Deals

Ganzhou Hemay Pharma Files for HK IPO with SDIC Securities Sponsorship

Fineline Cube May 30, 2025

China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with...

Company Deals

GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation

Fineline Cube May 29, 2025

Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD...

Company Medical Device

Abbott Laboratories Receives FDA Approval for Tendyne TMVR System

Fineline Cube May 29, 2025

US-based medical device giant Abbott Laboratories (NYSE: ABT) announced that it has received marketing approval...

Company Deals

AusperBio Secures $50M in Oversubscribed Series B+ Round to Advance Hepatitis B Therapy

Fineline Cube May 29, 2025

Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing...

Company Drug

BMS Gains European Approval for Opdivo Subcutaneous Formulation

Fineline Cube May 29, 2025

Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to...

Posts pagination

1 … 183 184 185 … 697

Recent updates

  • Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms
  • China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure
  • CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
  • Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China
  • Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Policy / Regulatory

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.